Related Experiment Videos
Hepatocellular carcinoma in a hepatitis B 'x' transgenic mouse model: A sequential pathological evaluation
Ritu Lakhtakia1, Vijay Kumar, Honey Reddi
1Department of Pathology, All India Institute of Medical Sciences, Aruna Asaf Ali Marg, New Delhi, India.
Journal of Gastroenterology and Hepatology
|January 10, 2003
Summary
Hepatitis B virus (HBV) X protein and c-myc genes collaborate to drive hepatocellular carcinoma development in a transgenic mouse model, revealing key steps in carcinogenesis.
Area of Science:
- Hepatology
- Oncology
- Molecular Biology
Background:
- Transgenic technology enables studying carcinogenesis and viral links to cancer.
- Hepatitis B virus (HBV)-related carcinogenesis research benefits from transgenic models.
- A transgenic mouse model expressing HBV X protein and c-myc was used to study liver cancer development.
Purpose of the Study:
- To pathologically evaluate the sequential steps of hepatocarcinogenesis.
- To understand the role of HBV X protein and c-myc in liver cancer development.
Main Methods:
- Detailed pathological evaluation of a transgenic mouse model.
- Analysis of liver tissue from birth to 28 weeks.
- Assessment of hepatocyte proliferation, apoptosis, and gene expression (c-myc, p53).
Main Results:
- Transgenic mice showed liver changes from birth, progressing from dysplasia to hepatocellular carcinoma by 28 weeks.
- Hepatocytes exhibited increased proliferation and apoptosis, with apoptosis declining as tumors developed.
- Neoplastic lesions showed high c-myc expression, unaltered p53, and altered succinic dehydrogenase but normal hepatic enzymes.
Conclusions:
- The collaborative action of HBx and c-myc genes disrupts cell growth and death, leading to hepatocellular carcinoma.
- This model provides insights into the prolonged latent period preceding liver cancer development.
- Understanding these molecular mechanisms is crucial for targeting HBV-related liver cancer.